Technical Data
E3375-30
Epidermal Growth Factor Receptor (EGFr)
Description:
The epidermal growth factor receptor (EGFr) is a 170kD transmembrane protein consisting of an extracellular EGF-binding domain, a short transmembrane region, and an intracellular domain with ligand-activated tyrosine kinase activity. Two ligands can activate EGFr: epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-a). When TGF-a binds to EGFr, receptor tyrosine kinase activity is upregulated, producing phosphorylation and an increase in cytosolic calcium within target cells. This triggers increased synthesis of DNA and the proliferation and differentiation of target cells. TGF-a is an important effector of malignant transformation in a variety of cells. EGFr is expressed in many normal epithelial tissues, particularly in the basal layers of strati ed epithelium and in squamous epithelium. Over-expression of EGFr has been observed in many types of neoplasia, as the result of gene ampli cation and/or increased protein transcription. EGFr over-expression has been detected in endometrial carcinoma, correlated with myometrial invasion, in lung neoplasms including metaplastic squamous epithelium, squamous cell carcinoma, adenocarcinoma, and neuroendocrine lung tumors, and in glioblastoma multiforme brain tumors. EGFr expression has also been reported in most head and neck carcinomas. Variable EGFr expression has been positively correlated with increasing tumor stage in transitional bladder, renal cell, and gastric carcinomas, and in inverse correlation to estrogen receptor (ER)-negative tumor status in breast carcinoma.

Applications:
Suitable for use in Immunohistochemistry and Western Blot. Other applications not tested.

Recommended Dilution:
Immunohistochemistry: 1:50-1:200. Enzyme digestion is required (Pepsin). Epitope retrieval is not required.
Optimal dilutions to be determined by the researcher.

Positive Control: Breast carcinoma

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile 40-50% glycerol, aliquot and store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG13G143Affinity Purified
SizeStorageShippingSourceHost
2ml4C (-20C Glycerol)Blue IceHumanMouse
Concentration:
~0.01mg/ml
Immunogen:
Human EGFr derived from A431 cells.
Purity:
Purified by affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 1% BSA, 0.1% sodium azide.
Specificity:
Recognizes human EGFr. Stains epidermal cells of skin, esophagus, kidney, testis, placenta and prostate. Positive staining appears as a linear to nely granular pattern in the cell membrane and adjacent cytoplasm, or as coarsely granular cytoplasmic staining. Does not recognize the highly homologous c-erbB-2 (HER-2) protein. Western Blot analysis with an EGFr vIII-transfected NIH-3T3 cell line con rmed this antibody recognizes the 145kD variant III form of EGFr in addition to recognizing the wild type form of EGFr.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Cohen, S., et al. (1982) J. Biol. Chem. 257:15231539. 2. Chen, W.S., et al., (1989) Cell 59:3343. 3. Pusztai, L., et al., (1993) J. Pathol. 169:914. 4. Ozane, B. and Richardson, C.S., (1986) J. Pathol. 149:191201 . 5. Gusterson, B., et al. (1984) Cell Biol. Int. Rep. 8:649658. 6. Damjanov, I., et al., (1986) Lab. Invest. 55(5):588592. 7. Niikura, H., et al., (1996) Human Pathol. 27(3):282289. 8. Rusch, V., et al., (1996) Ann. Thorac. Surg. 62:798810. 9. Agosti, R.M., et al., (1992) Virchows Arch. Pathol. Anat. 420:321325. 10. Christensen, M.E., (1998) Danish Med. Bull. 45(2):121134. 11. Neal, D.E., et al., (1985) Lancet 1:366368. 12. Toi, M., et al., (1989) Int. J. Cancer 43:220225.